Can money really be no object when cancer care is the subject?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.Clinical colorectal cancer · 2016
   Pooled it
2. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.Cancer control : journal of the Moffitt Cancer Center
   Trial
3. Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.BMJ open · 2025
   Article
4. To treat or not to treat? Oncologists' perceptions and experiences regarding overtreatment in end stage cancer patients.Frontiers in medicine · 2025
   Article
5. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.BMJ open · 2020
   Article
6. Low-value practices in oncology contributing to financial toxicity.Ecancermedicalscience · 2017
   Article
7. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.Medical oncology (Northwood, London, England) · 2016
   Article
8. Acquired resistance to immunotherapy and future challenges.Nature reviews. Cancer · 2016
   Article
9. Health Care Spending: Changes in the Perceptions of the Australian Public.PloS one · 2016
   Article
10. Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
    Article
11. Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.Cancer journal (Sudbury, Mass.)
    Review

Corrections and comments

• Commented on by
  ["The expensive" health care. Sneaky rationing or ration book?!].2015
• Commented on by
  Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.2015
• Commented on by
  Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer.2015
• Comment on
  First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as